VTYX Ventyx Biosciences, Inc.

Nasdaq ventyxbio.com


$ 6.01 $ 0.00 (0 %)    

Monday, 27-Oct-2025 04:56:33 EDT
QQQ $ 624.29 $ 0.00 (0 %)
DIA $ 474.82 $ 0.00 (0 %)
SPY $ 682.62 $ 0.00 (0 %)
TLT $ 91.02 $ 0.00 (0 %)
GLD $ 370.59 $ 0.00 (0 %)
$ 5.81
$ 6.76
$ 5.92 x 100
$ 6.02 x 36
-- - --
$ 0.78 - $ 7.82
12,475,428
na
414.3M
$ 0.90
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 02-27-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 02-27-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-23-2023 12-31-2022 10-K
12 11-04-2022 09-30-2022 10-Q
13 08-15-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-23-2022 12-31-2021 10-K
16 11-18-2021 09-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 ventyx-stock-is-rallying-thursday-whats-driving-the-surge

Ventyx Biosciences Inc (NASDAQ:VTYX) shares are surging Thursday after the company announced positive Phase 2 study results for...

 why-ventyx-vtyx-shares-soared-865-after-hours

Ventyx shares jumped 86.5% in after-hours trading after positive Phase 2 trial results.

 ventyx-biosciences-announces-positive-results-from-phase-2-trial-of-vtx3232-for-obesity-cardiovascular-risk-factors-vtx3232-monotherapy-achieved-80-reduction-in-hscrp-vtx3232-monotherapy-reduced-il-6-levels

Ventyx Biosciences, Inc. (Nasdaq: VTYX) ("Ventyx", "Company"), today announced positive results from its Phase ...

 clear-street-initiates-coverage-on-ventyx-biosciences-with-buy-rating-announces-price-target-of-11

Clear Street analyst Kaveri Pohlman initiates coverage on Ventyx Biosciences (NASDAQ:VTYX) with a Buy rating and announces P...

 ventyx-biosciences-q2-eps-038-beats-045-estimate

Ventyx Biosciences (NASDAQ:VTYX) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(...

 ventyx-biosciences-q1-eps-039-beats-049-estimate

Ventyx Biosciences (NASDAQ:VTYX) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION